Edwards Lifesciences: More Appeal For The Heart

Revenue grew 11% in 2025, driven by robust TAVR performance and accelerating TMTT. Management guides for 8-10% sales growth and adjusted EPS of $2.90–$3.05 in 2026, with TMTT sales expected to rise ~40%. Valuation has compressed to ~26x forward earnings, but a strong net cash position and ongoing share repurchases provide balance-sheet and capital-return support.

Analysis

TMTT momentum is creating a modular downstream market that benefits consumable and imaging vendors more than just valve OEMs — hospitals will buy more disposables, longer imaging lab hours, and ancillary software/licenses as centers scale procedures. Expect upstream catheter and imaging component suppliers to see a multi-quarter cadence uplift in reorder frequency; this favors names with high gross-margin consumable exposure and low capital-equipment dependency.

Competitive dynamics now hinge on system stickiness and platform economics: if an OEM can lock in hospitals via disposables, training, and imaging integrations, share shifts become sticky and translate into recurring revenue growth rather than one-off device wins. The main reversal vectors are reimbursement compression and one high-profile durability or safety signal from a randomized trial; both would materially widen short-term volatility and could reset market share assumptions within 6-12 months.

Near-term positioning should be catalyst-driven — earnings, CMS/regulatory headlines, and any announced trial milestones. The fund should think in layered timeframes: tactical (days–weeks) to harvest volatility ahead of binary events; medium-term (3–12 months) to capture share gains as centers ramp; and strategic (1–3 years) to play platform-level win/lose outcomes tied to consumables annuity growth. Liquidity and buyback optionality reduce tail bankruptcy risk but do not immunize the stock from event-driven drawdowns, so hedge sizing matters.

Key Decisions for Investors

• Long EW equity (base position) with a 12–18 month horizon to capture platform monetization and share gains; size to 2–3% of equity portfolio. Hedge tail risk by buying 9–12 month puts financing them with short-dated call sales (collar) around upcoming regulatory/earnings dates; target asymmetric payoff of 3:1 if positive adoption persists.
• Pair trade: long EW / short MDT (equal notional) for 6–12 months to isolate structural share gain in TMTT/TAVR platforms. Rationale: capture share shift while hedging macro and procedure-volume cyclicality; stop-loss if the spread widens 8% adverse in 30 days (reassess on trial/regulatory news).
• Supplier play: overweight GE (GE) and a high-consumable smaller cap (selectable on desk) for 3–9 months to benefit from increased imaging and disposables cadence as TMTT volumes scale. Use covered-call overlays if near-term IV compresses, and take profits on 20–30% moves.
• Event hedge: buy a small notional of EW long-dated calls (12–24 months) instead of straight equity if wanting convex upside on successful platform monetization with limited downside premium. Position size should be <1% of portfolio value to preserve convexity without overpaying for prolonged adoption risk.